PE20061310A1 - Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida - Google Patents

Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida

Info

Publication number
PE20061310A1
PE20061310A1 PE2006000360A PE2006000360A PE20061310A1 PE 20061310 A1 PE20061310 A1 PE 20061310A1 PE 2006000360 A PE2006000360 A PE 2006000360A PE 2006000360 A PE2006000360 A PE 2006000360A PE 20061310 A1 PE20061310 A1 PE 20061310A1
Authority
PE
Peru
Prior art keywords
dihydroquinoline
azabicyclo
oxo
oct
propyl
Prior art date
Application number
PE2006000360A
Other languages
English (en)
Spanish (es)
Inventor
Paul R Fatheree
Adam A Goldblum
Daniel Genov
S Derek Turner
Robert Chao
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PE20061310A1 publication Critical patent/PE20061310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2006000360A 2005-04-06 2006-04-03 Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida PE20061310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
PE20061310A1 true PE20061310A1 (es) 2007-01-23

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000360A PE20061310A1 (es) 2005-04-06 2006-04-03 Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida

Country Status (29)

Country Link
US (4) US7728004B2 (enExample)
EP (1) EP1874766B1 (enExample)
JP (2) JP5230407B2 (enExample)
KR (1) KR101322873B1 (enExample)
CN (1) CN101151264B (enExample)
AR (2) AR053208A1 (enExample)
AT (1) ATE479682T1 (enExample)
AU (1) AU2006232129B2 (enExample)
BR (1) BRPI0610657A2 (enExample)
CA (1) CA2603654C (enExample)
CY (1) CY1111275T1 (enExample)
DE (1) DE602006016586D1 (enExample)
DK (1) DK1874766T3 (enExample)
EA (1) EA012115B1 (enExample)
ES (1) ES2350495T3 (enExample)
HR (1) HRP20100629T1 (enExample)
IL (1) IL186023A (enExample)
MA (1) MA29403B1 (enExample)
MX (1) MX2007012438A (enExample)
MY (1) MY151075A (enExample)
NO (1) NO339699B1 (enExample)
NZ (1) NZ561900A (enExample)
PE (1) PE20061310A1 (enExample)
PL (1) PL1874766T3 (enExample)
PT (1) PT1874766E (enExample)
SI (1) SI1874766T1 (enExample)
TW (1) TWI377206B (enExample)
WO (1) WO2006108127A2 (enExample)
ZA (1) ZA200708071B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス, インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
HUE049642T2 (hu) * 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
US20260124194A1 (en) 2022-09-20 2026-05-07 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
JP5230407B2 (ja) 2013-07-10
WO2006108127A3 (en) 2007-01-04
PT1874766E (pt) 2010-11-30
NO339699B1 (no) 2017-01-23
JP2008535848A (ja) 2008-09-04
US7728004B2 (en) 2010-06-01
ES2350495T3 (es) 2011-01-24
NO20075574L (no) 2007-11-02
PL1874766T3 (pl) 2011-02-28
CN101151264B (zh) 2011-07-06
CA2603654C (en) 2014-05-27
WO2006108127A2 (en) 2006-10-12
IL186023A (en) 2011-09-27
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
AU2006232129B2 (en) 2012-07-12
CA2603654A1 (en) 2006-10-12
EA012115B1 (ru) 2009-08-28
AR110019A2 (es) 2019-02-13
EA200702161A1 (ru) 2008-04-28
MX2007012438A (es) 2007-12-05
NZ561900A (en) 2010-12-24
CY1111275T1 (el) 2015-08-05
CN101151264A (zh) 2008-03-26
DE602006016586D1 (de) 2010-10-14
IL186023A0 (en) 2008-01-20
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
US20140256769A1 (en) 2014-09-11
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
TW200643020A (en) 2006-12-16
HRP20100629T1 (hr) 2010-12-31
EP1874766A2 (en) 2008-01-09
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
KR20070116988A (ko) 2007-12-11
ZA200708071B (en) 2008-10-29
JP2012153725A (ja) 2012-08-16
US20160095849A1 (en) 2016-04-07
US20060229332A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
KR101322873B1 (ko) 2013-10-30
US9126994B2 (en) 2015-09-08
MY151075A (en) 2014-03-31
AR053208A1 (es) 2007-04-25
SI1874766T1 (sl) 2010-12-31
TWI377206B (en) 2012-11-21

Similar Documents

Publication Publication Date Title
AR046322A1 (es) Compuestos de amidoacetonitrilo, metodos para su preparacion y de sus intermediarios y su uso en composiciones antiparasitarias.
ES2411604T3 (es) Compuestos orgánicos
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
PE20120599A1 (es) Metodo para producir material de sabor
EA201171415A1 (ru) Ингибиторы белков семейства iap
AR110019A2 (es) Forma cristalina de un compuesto de quinolinona-carboxamida
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
ES2676600T3 (es) Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
AR062536A1 (es) Acilanilidas sustituidas y composicion farmaceutica
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ES2615057T3 (es) Materiales zeolíticos y métodos para su preparación usando compuestos de alqueniltrialquilamonio
UY29149A1 (es) Tiazolil-dihidro-indazoles
ECSP088267A (es) Un procedimiento mejorado para preparar compuestos de aminodiol protegidos con oxazodilina, utiles como intermediarios para el florfenicol
UY28039A1 (es) Granulados de meloxicam solubles en agua
BRPI0520252A2 (pt) método de desacilar sucralose-6-éster
NO20072290L (no) Organiske forbindelser.
AR078627A1 (es) N-((1r,2s,5r)-5-terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, forma cristalina, procedimiento de preparacion, composiciones farmaceuticas que los comprenden y uso del mismo para tratar diabetes, obesidad, enfermedades alerg
PE20071091A1 (es) Polimorfos de n-(3h-imidazol[4,5-b]piridin-2-ilmetil)-2-fluoro-4-metil-3-oxo-4-aza-5-alfa-androst-1-en-17-beta-carboxamida
BRPI0802215A2 (pt) mÉtodo de fabricaÇço de uma espuma de aspersço de poliisocianurato/poliuretano
PE20090192A1 (es) Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo
AR055761A1 (es) Procedimiento para preparar especies de aluminio
UY30798A1 (es) Sales de timo depresores farmacéuticamente aceptables y procesos para su manufactura

Legal Events

Date Code Title Description
FC Refusal